cupure logo
trumpdickdiescheneydick cheneypresidentpolicegovernmentwarbudget

Trump close to deal to allow Medicare coverage of weight loss drugs

Trump close to deal to allow Medicare coverage of weight loss drugs
The Trump administration is closing in on a deal to allow Medicare coverage of weight loss drugs by Eli Lilly and Novo Nordisk in some cases, according to multiple reports. The arrangement would be possible under a deal with the companies that would decrease the price of Novo Nordisk's Wegovy to $149 a month on the TrumpRX website for the lowest dose and Eli Lilly's Zepbound to $299, per the Wall Street Journal. Why it matters: A deal could significantly expand seniors' access to popular weight loss drugs while drastically decreasing the estimated cost of that coverage.It also could lead to a broader impact on people's access to these drugs, since Medicare often influences what private insurers choose to cover. The Wall Street Journal reported that the deal could also allow Medicaid coverage of the drugs.Endpoints News first reported the details of the emerging deal.Context: Medicare already covers GLP-1s for diabetes, heart disease and sleep apnea, and about half of seniors with obesity are already eligible for the drugs due to other conditions. In April, the Trump administration scrapped a Biden-era proposal to let Medicare and Medicaid cover GLP-1s to treat obesity. The plan would have cost some $40 billion over 10 years. This would be the latest in a line of deals between the White House and drugmakers to lower drug prices paid by Americans. This is a developing story. Check back for updates.

Comments

Similar News

World news